FLT3 and acute myeloid leukemia: Quizartinib (AC220), gilteritinib, MLN-518, sunitinib and ponatinib are being studied in clinical trials.253–257 Although these FLT3 inhibitors exhibit potent activity against AML in clinical trials, acquired drug resistance and relapse still remain challenges for FLT3-targeted therapy.